UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

April25, 2023

Date

of Report (Date of earliest event reported)

BIOAFFINITY

TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41463	46-5211056
(State<br> or other jurisdiction<br><br> <br>of<br> incorporation)	(Commission<br><br> <br>File<br> Number)	(I.R.S.<br> Employer<br><br> <br>Identification<br> Number)

22211W Interstate 10

Suite1206

SanAntonio, Texas 78257

(210)

698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
Common<br> Stock, par value $.007 per share	BIAF	The<br> Nasdaq Stock Market LLC
Tradeable<br> Warrants to purchase Common Stock	BIAFW	The<br> Nasdaq Stock Market LLC

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item8.01. Other Events.

On April 25, 2023, the Company issued a press release announcing that it will be making a presentation at the Cleveland Clinic’s Advances in Early Lung Cancer Detection annual symposium in Cleveland, Ohio, on April 27, 2023. The press release is attached as Exhibit 99.1 to this Form 8-K.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of bioAffinity Technologies, Inc., dated April 25, 2023.
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOAFFINITY<br> TECHNOLOGIES, INC.
By:	/s/ Maria Zannes
	Maria<br> Zannes
	President<br> and Chief Executive Officer

Dated: April 25, 2023

Exhibit99.1

---

bioAffinityTechnologies Presents at Cleveland ClinicLung Cancer Symposium

SANANTONIO, Texas (April 25, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland Clinic’s invitation-only Advances in Early Lung Cancer Detection annual symposium in Cleveland, Ohio, on April 27, 2023.

The presentation by Vivienne I. Rebel, MD, PhD, bioAffinity Technologies Executive Vice President and Chief Science and Medical Officer, will focus on advancements in CyPath^®^ Lung, the Company’s noninvasive test for detection of early-stage lung cancer. CyPath^®^ Lung uses flow cytometry and artificial intelligence to analyze the lung microenvironment to identify cell populations that accurately predict cancer in patients at high risk for lung cancer.

The fourth annual Advances in Early Lung Cancer Detection symposium brings together global leaders in the field of lung cancer, including physicians, advocates and industry, to accelerate the development and implementation of new technologies and methods to find lung cancer at the earliest stages when it is most treatable. This is bioAffinity Technologies’ fourth invitation to present before symposium attendees.

AboutbioAffinity Technologies, Inc.

---

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company’s first product, CyPath^®^ Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect^®^ Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn and Twitter.

Aboutthe Cleveland Clinic

---

The Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 to provide outstanding patient care based upon cooperation, compassion and innovation, the Cleveland Clinic has pioneered many medical breakthroughs and is consistently named one of the nation’s best hospitals.

Forward-LookingStatements

---

This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Contacts

---

bioAffinityTechnologies

Julie Anne Overton

Director of Communications

jao@bioaffinitytech.com

LHAInvestor Relations

Tirth T. Patel

tpatel@lhai.com